To explore the effects of sleep cognitive behavioral therapy combined with escitalopram tablets on negative emotions and sleep function of patients with depression and anxiety in our hospital.

From April 2021 to May 2023, patients with depression complicated with anxiety in our hospital were divided into control group and experimental group according to treatment methods. The control group was given escitalopram orally, 10 mg each time, qd for 8 weeks; in the experimental group, CBT-I (including sleep health education, stimulation control and other modules) was added on the basis of the control group, once a week for 60-90 min, and the course of treatment was 8 weeks. The clinical efficacy, negative emotional scores [using Hamilton Anxiety Scale (HAMA) and Hamilton Depression Scale (HAMD)], sleep quality [using Pittsburgh Sleep Quality Index (PSQI)], social function [using Social Disability Screening Scale (SDSS)], cognitive function [using Mini-Mental State Examination (MMSE)], serum neuron-specific enolase (NSE) and neuropeptide Y (NPY) levels, medication compliance (using Morisky medication compliance questionnaire), and recurrence rate were compared between the two groups.

A total of 126 patients with depression and anxiety were screened and 100 patients were enrolled, including 48 patients in the control group and 52 patients in the experimental group. After treatment, the total effective rate of the treatment group was 82.69% (43 cases /52 cases), which was significantly higher than that of the control group 62.50% (30 cases/48 cases) (P<0.05). The HAMA scores in the treatment group and control group were (8.33±4.61) and (14.66 ±5.29) scores, respectively; the HAMD scores were (6.87±2.42) and (10.76±2.63), respectively; the PSQI scores were (7.06±1.11) and (10.69±1.03), respectively; the serum NSE levels were (10.35±1.46) and (12.26±1.55) μg·L^-1; the NPY levels were (431.55±97.22) and (314.22±41.38) μg·L^-1, respectively. The above indexes in the treatment group were significantly lower than those in the control group (all P<0.05). The recurrence rate of the treatment group and control group was 3.85% (2 cases /52 cases) and 16.67% (8 cases /48 cases), respectively, without statistically significant difference (P>0.05). No serious adverse events occurred during the intervention period in both groups, and there was no significant difference in the incidence of adverse events (P>0.05).

Cognitive behavioral therapy for insomnia combined with escitalopram tablets can effectively alleviate negative emotions, improve sleep function and reduce recurrence rate in patients with depression complicated with anxiety in our hospital, with good clinical efficacy.